Announcements Trials
Browse Landscape

Phase

Phase 3 27Phase 2 8Phase 1/2 5Phase 1 4Phase 4 1

Status

Recruiting 3Completed 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1

Conditions

Breast Neoplasms 57Carcinoma, Non-Small-Cell Lung 46Ovarian Neoplasms 31Stomach Neoplasms 22Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Lung Neoplasms 18Neoplasm Metastasis 17Fallopian Tube Neoplasms 14Triple Negative Breast Neoplasms 13Esophageal Neoplasms 13Esophageal Squamous Cell Carcinoma 10Colorectal Neoplasms 9Carcinoma, Ovarian Epithelial 9Melanoma 8Head and Neck Neoplasms 8Endometrial Neoplasms 8Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Carcinoma, Renal Cell 6Adenocarcinoma of Lung 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Advanced Solid Tumors 5Testicular Neoplasms 4Testicular Germ Cell Tumor 4Recurrence 4Carcinoma, Transitional Cell 4

Interventions

pembrolizumab 21lenvatinib 8Paclitaxel 5patritumab deruxtecan 3enfortumab vedotin 2belzutifan 2Tretinoin 2Surgical Procedures, Operative 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Carboplatin 2Capecitabine 2tremelimumab 1trametinib 1poly ICLC 1epacadostat 1efineptakin alfa 1durvalumab 1dabrafenib 1Ramucirumab 1Radiotherapy 1Radiosurgery 1Radiation 1Pemetrexed 1Levoleucovorin 1Immunotherapy 1Histamine H2 Antagonists 1Histamine Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Parkinson Disease 4, Autosomal Dominant Lewy Body × Paclitaxel × Clear all
NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04165070 2026-05-18

MK-3475-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
450 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06445972 2026-05-12

MK-3475-06D

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
210 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT05342636 2025-12-17

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Merck Sharp & Dohme LLC

Phase 1/2 Completed
90 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Ludwig Institute for Cancer Research

Phase 1/2 Completed
73 enrolled 18 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡